Werewolf Therapeutics (HOWL) stock

Cancer immune therapies , market cap $49.6M

Therapies that stimulate immune system

Worth $49.6M

$0.97

-3.96%

As of Tuesday's close · Live for Pro members at the open

Quality Score

Below Average

In its industry

#96of 281

Biotech

Checks firing

5of 14

Trending up

From 52-week high

-19.8%

under its best in a year

HOWL's Quality Score was unchanged on Tue, Nov 10, at 3.

Follow HOWL's news. Pro members can get an alert when Werewolf Therapeutics files news, and see its trials, share raises, and its CEO's filings.

Get an alert when HOWL files newsSee it live, free until Thursday morning. No account. No card. Then keep going with a free account.

We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.

Next2028“…to be fully funded through topline results from the pivotal CRPS-RISE Phase 3 clinical trial expected in 2028…”Trial data · SEC filing · Aug 21

Cash$22M in cash. One of the last four quarters brought cash in while the others used it.On Jun 30 · the company says “into 1H 2029”

Key facts on HOWL

Key facts on HOWL
Holding it back	Free cash flow -$30M from the SEC filings and Massive's market data, 61% of its market value
Latest filing	8-K, Nov 9 Issued a release: "Werewolf Therapeutics’ Clinical Data for WTX-124 and WTX-330 Presented at the Society for Immunotherapy of Cancer’s (SITC) 2026 Annual Meeting"

1 more reason behind HOWL's 3, free with an account →2 more reasons behind HOWL's 3, for Pro members.

HOWL in the news

TodayNo story names it yet.

Cash$22M in cash. One of the last four quarters brought cash in while the others used it.On Jun 30 · the company says “into 1H 2029”

HOWL catalysts

Coming up

After its last 4 reports it closed -9.2% on average, higher 1 of 4 times.

What's next for HOWL, and how long its cash lasts

Next step the company has named

2028“…Therapeutics expects the combined company to be fully funded through topline results from the pivotal CRPS-RISE Phase 3 clinical trial expected in 2028 and a planned New Drug Application”Trial data · SEC filing · Aug 21

What it means: the first look at a trial’s main results, as the company reports them.

For Pro members: 30 filings.

Cash runway Jun 30 balance sheet

$22M in cash

One of the last four quarters brought cash in while the others used it, so an average says little about the next.

What it means: a runway is counted only when each of the last four quarters used cash. The company's estimate is “into 1H 2029” (8-K, Aug 21).

For Pro members: the cash used each quarter, and the math.

Dilution on the horizon

Shelf registration (S-3, filed May 8, 2025)
At-the-market share sales program (S-3, filed May 8, 2025)

For Pro members: 1 raise and its amount, and the share count against a year ago.

Insiders

Director Luke Evnin sold 143,199 shares on Jul 7, under a planned sale. 17 more insider trades this year.

From Form 4: open-market buys and sales only.

Get an alert when Daniel Hicklin buys or sells

For Pro members: every trade, and Daniel Hicklin’s 2 filings and quotes.

Get an alert when HOWL files newsA free account. No card.

See every upcoming FDA date →

FDA dates in the next 60 days

Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.

DateStockDrug

In 12 daysFDA decisionIn 12 days · FDA decisionCAPRCapricor TherapeuticsDeramiocelCAPRCapricor Therapeutics · $500MDeramiocelFDA decision due (PDUFA)
In 12 daysFDA decisionIn 12 days · FDA decisionSVRASavaraMolgramostimSVRASavara · $900MMolgramostimFDA decision due (PDUFA)
In 42 daysFDA decisionIn 42 days · FDA decisionMLYSMineralys TherapeuticsLorundrostatMLYSMineralys Therapeutics · $1.3BLorundrostatFDA decision due (PDUFA)

14 more FDA dates and 103 trial data dates in the next 60 days, each on the FDA calendar. Pro members see whether each company's cash lasts past its date, with an optional alert before it. See all 151 dates, ranked →

Why HOWL scores 3

Below Averagefor quality, not price, 5 of 14 chart checks firingWhat the Quality Score means

+5Chart checks 5 of 14 firing right now, one point each
+1Run-up 53% over 6 months

Size subtracts
Volatility subtractsA daily range of 5% or more with nothing behind it (no profit or cash flow, sales shrinking, or 10% more shares outstanding with no free cash flow): -1, or -2 from 8%.
Cash flow subtracts-1 when free cash flow over the last four quarters is negative.

No effect today: Long-term trend, Profit, Growth, Dilution, Persistence, and News.

What every line is worth, and the reason behind it, on HOWL and every other stock.Get in free →

Price, score, chart checks, and the industry rank are from a snapshot taken at 10:45 PM ET, at least 15 minutes behind. How we rank stocks.

Tested. Our top-scored stocks returned 2.2x the average stock over the next month. Reconstructed after the fact; recorded live since Sep 9, 2026. How we tested it

Alert me when HOWL's Quality Score turns up

A free account. No card.

How HOWL ranks in Biotech

HOWL is #96 of 281 by Quality Score.

How HOWL ranks in Biotech
Rank	Stock	Checks	Quality Score
1	ONCBeOne Medicines	8/14	24
2	VCELVericel	8/14	22
3	ETONEton Pharmaceutcials	9/14	20
	HALOHalozyme Therapeutics		Open for its score
	HELPHelus Pharma		Open for its score
	HRMYHarmony Biosciences		Open for its score
	HURATuHURA Biosciences		Open for its score
96	HOWLWerewolf Therapeutics	5/14	3

When does HOWL report earnings, and what happens after?

Expected to report Thu Nov 12, before the open (in 2 days).

What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.

What HOWL reported on Jul 31, 2026

The quarter

The figures are not read from the release yet.

The filing on EDGAR

Where the sales came from

HOWL's results filing gives no sales by line in a table we read.

The outlook

No outlook figures read from this release.

In the company's words

“Based on its current operating plan, the Company expects to be able to fund its operations into the second quarter of 2027.”

From its results filing (SEC filing · Jul 31)

The numbers

Market value: $49.6M; today

No analyst estimates on Breakaway: every figure here is filed.

The whole report on HOWL: every line of its sales, every outlook beside the one it replaced, and the company's words, for Pro members.

Close after the report, last 3

-9.5%+9.7%-29.4%

Mar 27May 7Jul 31

Reported	When	Gap	Reaction	5 days
Jul 31, 2026Before open	Before open	-0.1%	-29.4%	-19.5%
May 7, 2026After close	After close	-0.3%	+9.7%	-12.5%
Mar 27, 2026Before open	Before open	-2.7%	-9.5%	+17.0%

HOWL closed higher after 1 of its last 4 reports.

All 4 reports, and HOWL's Quality Score going into each

Everyone reporting earnings this week

HOWL has 5 of 14 chart checks firing

Trend1 of 5 shown

MA FAN 21 EMA W.EMA HH/HL 52W HI

Volume1 of 3 shown

VOL VDU U/D VOL

Tight range1 of 3 shown

ATR SQZ SQUEEZE NR7

Buying1 of 3 shown

OBV+CLOSE HI SPRING

The other 10 checks on HOWL, and all 14 on every stock.Get in free →

HOWL RSI today: 46.4, below its 50-day, above its 200-day

Not scored

RSI 46.4, MACD below signal, below its 50-day, above its 200-day. Not scored.13 readings

The deep dive on HOWL

What it does and how it makes money2 findingsFor Pro members2 findings on what HOWL does and how it makes money, for Pro members
Where it stands2 findings$22.0M in cash and short-term investments against $32.1M of debt on Jun 30, 2026.Balance sheet of Jun 30, 2026, filed Jul 31, 2026
Who holds and trades it2 findingsFor Pro members2 findings on who holds and trades HOWL, for Pro members

5 more findings on HOWL, each with its source, for Pro members.

HOWL share count over time

Shares: 8.0% more than a year ago (to Jun 30).

Shares of HOWL outstanding, as filed
Shares outstanding	As of
48.6M	Jul 27, 2026
48.6M	May 1, 2026
48.6M	Mar 20, 2026
48.5M	Oct 29, 2025

Offerings, shelves, and splits of HOWL, from its filings
From its filings	Filed
Registered shares for a later sale (S-3)	May 8, 2025
Set up an at-the-market program for up to $25M of shares, about 50% of its market value	Feb 9, 2024

HOWL insider trades

One insider sold $320K across 8 filings in the last 6 months. No open-⁠market buys on record. The newest:

SellRA Capital Management, L.P.$136K10% ownerat $0.35 on Jun 17, filed Jun 22

SellRA Capital Management, L.P.10% owner$136Kat $0.35 on Jun 17, filed Jun 22

All 8 insider filings on HOWL from the last six months, for Pro members.

All HOWL insider trades

Which ETFs hold HOWL?

In ETFs: HOWL is 0.0% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.

About Werewolf Therapeutics

Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions. It is leveraging the proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. It has one reportable segment, which focuses on the discovery and development of cancer therapeutics.

14 employeesWatertown, MAwerewolftx.com

Here is what Pro members see.

The same page for Pro members, on Microsoft
Its Quality Score and rank, the line that drives it, and the live price.
The full chart
A year of candles to start, out to the whole history, with insider trades marked and the Quality Score under the price.
Every line of the score
Price action, the company, and signals, each with its points, on HOWL and every other stock.
FDA dates, counted down
Each date in the company's words, its cash against the date, and an optional alert before it.
CEOs buying their own stock
Every CEO buy, biggest names first. Sort, filter, save the list, and set optional alerts.
Congress trades
A member's trades, newest first, each with its amount. Sort and filter the whole list.
14 chart checks, read for you
The ones firing on the stock, each in plain words, its rule a tap away.
Earnings, week by week
Who reports each day, and how each stock took its last four reports.
The market map
Every stock a box, colored by its Quality Score.
Themes, ranked live
Each theme's stocks ranked by Quality Score, live. Here, AI chips.
The top 10, every day
The ten highest Quality Scores at each close, kept day by day, week by week.
Optional alerts, your way
Pick a stock, a score, a price, a filing, or a whole scan. It tells you by push or email.
Your watchlist, scored
Your stocks by Quality Score, today's move, or name.
On your phone and your laptop
The same account and watchlist on both, each laid out for its screen.

Prices refresh every 2.5 seconds during market hours.
Optional alerts by push, email, or the bell.
Add it to your Home Screen and it opens like an app.

Pro members see every line of every stock's score.

What would turn HOWL's score around: 7 things
3 more filings explained, a plain line each
Real-⁠time prices, no delay

BreakawayJun 22RA Capital Management, L.P. sold HOWL$136K at $0.35, filed Jun 22

Alerts are optional.

See HOWL's 14 chart checks

See it live, free until Thursday morning. No account. No card. Then keep going with a free account.

Straight AnswersStraight Answers

As of Nov 10, 2026: HOWL's Quality Score is 3 (Below Average), #96 of 281 in Biotech. Insiders sold $320K in the last 6 months (Form 4).

What does HOWL's Quality Score say?

HOWL scores 3 today, which Breakaway calls Below Average. It is #96 of 281 in Biotech by Quality Score, with 5 of 14 chart checks firing. Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.

What is HOWL's Quality Score?

HOWL scores 3 today, which Breakaway calls Below Average (0 to 5). That is #96 of 281 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind HOWL's 3.

Are insiders buying HOWL?

One insider sold $320K across 8 filings in the last 6 months. No open-⁠market buys on record. The newest is RA Capital Management, L.P., 10% owner, who sold $136K on Jun 17. Every filing, with the scored weight, for Pro members.

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.